Du har inte javascript påslaget. Det innebär att många funktioner inte fungerar. För mer information om Vinnova, ta kontakt med oss.

E!114537, PROPEL, Uppsala Universitet

Diarienummer
Koordinator Uppsala universitet - Institutionen för kemi - Ångström
Bidrag från Vinnova 1 949 953 kronor
Projektets löptid oktober 2020 - januari 2023
Status Avslutat
Utlysning Eurostars – för forskande små och medelstora företag

Viktiga resultat som projektet gav

To determine the invitro therapeutic efficacy of chemically (guanidinium) modified siRNA we have designed a post-synthetic chemically (guanidinium) modified oligonucleotide through hydrazone linkage. As a proof of concept, we introduced our aldehyde modification on STAT3 and CHMP targeting siRNAs with variable aldehydes on the overhang positions. The aldehyde-modified oligonucleotides were subjected to condensation with hydrazide moiety which is linked with guanidinium units and shown a potential gene knockdown capability in cancer cells.

Långsiktiga effekter som förväntas

We have developed a universal chemical modification strategy to synthesize chemically modified oligonucleotides through post-synthetic modification. In this work, we have synthesized siRNAs with variable aldehyde functionalities which allows the chemical functionalization of any molecule of interest through hydrazone chemistry. We tested this chemical modification on two different siRNAs which showed a comparable knockdown in targeted genes.

Upplägg och genomförande

Initially, the synthesis of the building block required for introducing aldehyde and guanidine functionality on oligonucleotides was optimized separately in our laboratory. Subsequently, the building block was introduced into oligonucleotides of targeting genes were synthesized and purified over time. Later the ligand was conjugated to aldehyde-functionalized oligos through hydrazone chemistry under physiological conditions. After all the guanidinium-conjugated oligonucleotides which target STAT3 and CHMP genes were produced and tested on cancer cell lines.

Texten på den här sidan har projektgruppen själv formulerat. Innehållet är inte granskat av våra redaktörer.

Senast uppdaterad 31 januari 2023

Diarienummer 2020-03601